

Technology Appraisal Committee Meeting (Committee B)

Minutes: **Confirmed**

Date and Time: **Wednesday 2 March, 10am to 5pm**

Venue: **Prospero House**
241 Borough High Street
London
SE1 1GA Or

Present:	1. Dr Amanda Adler (Chair) 2. Dr Miriam McCarthy (proxy Vice Chair) 3. Dr Jeff Aronson 4. Professor John Cairns 5. Mr Mark Chapman 6. Dr Mark Glover 7. Dr Rebecca Kearney 8. Dr Sanjay Kinra 9. Mr Christopher O'Regan 10. Professor Stephen Palmer 11. Professor John Poundsford 12. Mr Alun Roebuck 13. Dr Nigel De-Kare Silver 14. Dr Marta Soares 15. Dr Nicky Welton 16. Mr Nigel Westwood	Present for all notes Present for notes 1 to 18 Present for all notes Present for all notes Present for all notes
-----------------	---	--

In attendance:

Meindert Boysen	Programme Director, National Institute for Health and Care Excellence	Present for all notes
Dr Melinda Goodall	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Jeremy Powell	Project Manager, National Institute for Health and Care Excellence	Present for all notes
Helen Tucker	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 1 to 18
Raisa Sidhu	Technical Adviser,	Present for notes 1 to 18

	National Institute for Health and Clinical Excellence	
Victoria Kelly	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 19 to 33
Dr Rosie Lovett	Technical Adviser, National Institute for Health and Clinical Excellence	Present for notes 19 to 3
Professor Matt Stevenson	Technical Director, School of Health and Related Research	Present for notes 1 to 16 and for notes 19 to 29
Dr Inigo Bermejo	Research Associate, School of Health and Related Research	Present for notes 1 to 16
Dr Katy Cooper	Senior Research Associate, School of Health and Related Research	Present for notes 1 to 16
Dr Shuaib Nasser	Clinical expert, Consultant Physician in Allergy & Asthma, Cambridge University Hospitals NHS Foundation Trust, nominated by the British Society of Allergy and Clinical Immunology (BSACI)	Present for notes 1 to 14
Professor Andrew Wardlaw	Clinical expert, Professor of Allergy and Respiratory Medicine, University of Leicester and University Hospitals of Leicester, nominated by the RCP	Present for notes 1 to 14
Lehanne Sergison	Patient expert, nominated by Asthma UK	Present for notes 1 to 14

Non-public observers:

Linda Grainger	Senior Medical Editor, NICE	Present for notes all notes
Cathryn Hall	Project Manager, NICE	Present for notes all notes
Chloe Kastoryano	Public Involvement Adviser, NICE	Present for notes 1 to 18
Edgar Masanga	Business Analyst - Resource Impact Assessment, NICE	Present for notes 1 to 18

Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of mepolizumab for treating severe eosinophilic asthma and cabazitaxel for treating hormone-relapsed metastatic prostate cancer after a docetaxel-containing regimen (review of TA255).
2. The Chair welcomed Dr Mark Glover to his first meeting as a member of the Appraisal Committee.
3. The Chair informed the Committee of the non-public observers at this meeting: Linda Grainger, Chloe Kastoryano and Edgar Masanga.
4. Apologies were received from Dr Ray Armstrong, Dr Neil Iosson, Professor Ruairidh Milne, Dr Sanjeev Patel, Dr Danielle Preedy and Professor Ken Stein.

Any other Business

5. The Committee were given an update on developments relating to the Cancer Drugs Fund.

Appraisal of mepolizumab for treating severe eosinophilic asthma [ID798]

Part 1 – Open session

6. The Chair welcomed the invited experts: Professor Matt Stevenson, Dr Inigo Bermejo, Dr Katy Cooper, Dr Shuaib Nasser, Professor Andrew Wardlaw and Lehanne Sergison to the meeting and they introduced themselves to the Committee.
7. The Chair welcomed company representatives from GlaxoSmithKline to the meeting.
8. The Chair asked all Committee members to declare any relevant interests
 - 8.1. Dr Amanda Adler, Dr Jeff Aronson, Professor John Cairns, Mr Mark Chapman, Dr Mark Glover, Dr Rebecca Kearney, Dr Sanjay Kinra, Dr Miriam McCarthy, Mr Christopher O'Regan, Professor Stephen Palmer, Professor John Poundsford, Mr Alun Roebuck, Dr Nigel De-Kare Silver, Dr Marta Soares, Dr Nicky Welton and Mr Nigel Westwood all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of mepolizumab for treating severe eosinophilic asthma.
9. The Chair asked all NICE Staff to declare any relevant interests.
 - 9.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the

technologies to be considered as part of the appraisal of mepolizumab for treating severe eosinophilic asthma.

10. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
 - 10.1. Professor Matt Stevenson, Dr Inigo Bermejo, Dr Katy Cooper and Lehanne Sergison declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of mepolizumab for treating severe eosinophilic asthma.
 - 10.2. Dr Shuaib Nasser declared a personal specific financial interest as he has received financial support from GlaxoSmithKline.
 - 10.2.1. It was agreed that this declaration would not prevent Dr Nasser from participating in this section of the meeting
 - 10.3. Professor Andrew Wardlaw declared a personal specific financial interest as he has received financial support for research and has attended advisory boards for GlaxoSmithKline (though not related to mepolizumab) and other pharmaceutical companies.
 - 10.3.1. It was agreed that this declaration would not prevent Professor Wardlaw from participating in this section of the meeting
11. The Chair introduced the lead team, Dr John Pounsford, Dr Marta Soares and Mr Nigel Westwood who gave presentations on the clinical effectiveness and cost effectiveness of mepolizumab for treating severe eosinophilic asthma.
12. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
13. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960" and all public attendees left the meeting.
14. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

15. Discussion on confidential information continued. This information was supplied by the company.
16. The Evidence Review Group representatives left the meeting.
17. The committee decision was based on consensus.
18. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

Appraisal of cabazitaxel for treating hormone-relapsed metastatic prostate cancer after a docetaxel-containing regimen (review of TA255) [ID889]

Part 1 – Open session

19. The Chair welcomed the invited experts: Professor Matt Stevenson to the meeting and they introduced themselves to the Committee.
20. The Chair welcomed company representatives from Sanofi to the meeting.
21. The Chair asked all Committee members to declare any relevant interests
 - 21.1. Dr Amanda Adler, Dr Jeff Aronson, Professor John Cairns, Mr Mark Chapman, Dr Mark Glover, Dr Rebecca Kearney, Dr Sanjay Kinra, Dr Miriam McCarthy, Mr Christopher O'Regan, Professor Stephen Palmer, Professor John Poundsford, Mr Alun Roebuck, Dr Marta Soares, Dr Nicky Welton and Mr Nigel Westwood all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of cabazitaxel for treating hormone-relapsed metastatic prostate cancer after a docetaxel-containing regimen (review of TA255).
22. The Chair asked all NICE Staff to declare any relevant interests.
 - 22.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of cabazitaxel for treating hormone-relapsed metastatic prostate cancer after a docetaxel-containing regimen (review of TA255).
23. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
 - 23.1. Professor Matt Stevenson declared that he knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of cabazitaxel for treating hormone-relapsed metastatic prostate cancer after a docetaxel-containing regimen (review of TA255).
24. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
25. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
26. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be

prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.

27. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

28. Discussion on confidential information continued. This information was supplied by the company.
29. The Evidence Review Group representative left the meeting.
30. The Committee continued to discuss the clinical and cost effectiveness of cabazitaxel for treating hormone-relapsed metastatic prostate cancer after a docetaxel-containing regimen (review of TA255).
31. The committee decision was based on consensus.
32. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Date, time and venue of the next meeting

33. Wednesday 6 April 2016 at 10 Spring Gardens, London SW1A 2BU